Literature DB >> 9126172

Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.

D A McRitchie1, H R Cartwright, G M Halliday.   

Abstract

Using unbiased quantitative techniques, we evaluated the effect of Parkinson's disease on the regional size and the number of tyrosine hydroxylase-producing neurons and all neurons in the midbrain A8 and A10 dopaminergic cell groups located adjacent to the substantia nigra. Seven patients with Lewy body Parkinson's disease were evaluated and compared with five controls. Four of the patients with Parkinson's disease had additional neuropathology, and the effect of concomitant pathology on A10 populations was also determined. Degeneration was not observed in the A8 regions of any patient, and only certain A10 nuclei were affected by the disease. The parabrachial pigmented nucleus situated dorsal to the substantial nigra, and the parapeduncular nucleus located rostromedially were significantly reduced by 40-50% in patients with Parkinson's disease. Few differences were found between patients with or without additional pathology, suggesting a similar pathogenic mechanism to that observed in the substantia nigra of these patients. However, patients with additional pathology also had serotonergic cell loss in the caudal linear nucleus. There was a reduction in tyrosine hydroxylase immunoreactivity but no overt neurodegeneration in other A10 regions, suggesting the disease may also influence the production of dopamine in some surviving neurons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126172     DOI: 10.1006/exnr.1997.6418

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  40 in total

1.  Effects of cortical and striatal dopamine D1 receptor blockade on cued versus noncued behavioral responses.

Authors:  Won Yung Choi; Cecile Morvan Campbell; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

2.  Mosaic aging.

Authors:  Lary C Walker; James G Herndon
Journal:  Med Hypotheses       Date:  2010-01-27       Impact factor: 1.538

3.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

4.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

Review 5.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 6.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

7.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

Review 8.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

9.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

10.  The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.

Authors:  Kay Seidel; Josefine Mahlke; Sonny Siswanto; Reijko Krüger; Helmut Heinsen; Georg Auburger; Mohamed Bouzrou; Lea T Grinberg; Helmut Wicht; Horst-Werner Korf; Wilfred den Dunnen; Udo Rüb
Journal:  Brain Pathol       Date:  2014-09-12       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.